News | September 10, 2024
Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Konieczny has served as Interim CEO since April 2024
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Subscribe To Our Newsletter & Stay Updated
